Aptima® HPV +ThinPrep® Cervical Health

Cervical disease screening is an essential component of our efforts in women’s health. Hologic is the leader in Pap and human papillomavirus (HPV) testing. The ThinPrep Pap test helps healthcare providers and laboratory professionals detect the presence of abnormal cervical cells, and the Aptima HPV assays identify high-risk HPV mRNA that is indicative of the HPV infections most likely to lead to cervical disease.1-3  

Know the Facts

The Pap test has been the most successful cancer screening program in history.4

The rate of cervical cancer, which was a leading cause of death among women, has fallen by more than 70 percent since the Pap test was introduced over 80 years ago.5 Previously, cervical cancer was the leading cause of cancer death in women, but now it is the fifteenth most frequent.

Reducing cervical cancer incidence requires a comprehensive strategy.

Such a strategy will include screening options that take into account disparities that underserved women face. This strategy should focus on reducing preventive screening gaps by:

  • Implementing provider and patient education
  • Providing access to vaccinations
  • Offering Pap + HPV (co-testing)

Description

Leading the charge in cervical disease prevention with the ThinPrep® system and Aptima® HPV assays

Hologic has remained an unwavering advocate for women’s health for more than two decades. Our goals as a company are intrinsically tied to changes in best-practices for women’s health, applying the latest findings in diagnostic medicine to the development of new products and technologies in response to the emergence of new discoveries in medicine. Cervical disease screening is an essential component of our efforts in women’s health. Hologic is the leader in Pap and human papillomavirus (HPV) testing. The ThinPrep Pap test helps healthcare providers and laboratory professionals detect the presence of abnormal cervical cells, and the Aptima HPV assays identify high-risk HPV mRNA that is indicative of the HPV infections most likely to lead to cervical disease.1-3

Features

Curabitur accumsan auctor ipsum, eget aliquam tellus dignissim id. Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas. Sed vehicula scelerisque lacus id ultrices. Nullam vestibulum pharetra orci vel venenatis. Proin in pulvinar lorem, sed tempor felis. Cras tincidunt non felis imperdiet lobortis. Nulla nec nisl tempor, tincidunt lectus quis, tincidunt leo. Quisque laoreet ac velit fringilla tempor. Nullam a sollicitudin tellus. Curabitur et nulla quis diam porttitor tempor sed eu magna. Sed magna magna, fringilla vel luctus at, eleifend vitae risus. Fusce maximus pellentesque risus at ornare. Ut fermentum semper elit.

More Products

Panther Fusion® Open Access™

Laboratory Developed Tests (LDTs) are an essential part of diagnostics. Patients with certain medical conditions depend on these in-house developed tests when other options are not available. Save time and increase efficiency by consolidating your LDTs and IVD assays on the fully automated, sample-to-result, Panther Fusion system using the Open Access™ functionality.

Aptima® Vaginal Health

The Aptima vaginitis panel from Hologic consists of molecular nucleic acid amplification tests (NAAT) to aid in the detection of vaginosis and vaginitis. Our assays detect the three most common causes of infectious vaginitis: bacterial vaginosis, candida vaginitis and trichomoniasis.

Aptima® HIV-1 Quant Dx Assay

Dual-claim assay to confirm HIV-1 infection and measure viral load.
 

Aptima® Herpes Simplex 1 & 2 assay

Globally, over 4.1 billion people are infected with HSV-1 and HSV-2 and the signs and symptoms can overlap.1 It is only through laboratory tests that these subtypes can be differentiated, which is important for managing herpes infections and identifying the risk of transmission to neonates and among sex partners.2,3